(2β,5α,6β,17ξ,18α)-13-Methoxyvoaluteine
|
|
(2β,5α,6β,17ξ,18α)-13-Methoxyvoaluteine Eigenschaften
- Siedepunkt:
- 565.1±50.0 °C(Predicted)
- Dichte
- 1.29±0.1 g/cm3(Predicted)
- pka
- 7.50±0.60(Predicted)
Sicherheit
(2β,5α,6β,17ξ,18α)-13-Methoxyvoaluteine Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
The leaves of Tabernaemontana pachysiphon Stapf. contain this alkaloid which has been isolated by thin layer chromatography of the alkaloidal extract. It gives an ultraviolet spectrum consisting of absorption maxima at 217-9, 243-6 and 389-391 nm.Einzelnachweise
Crooks, Robinson, 1. Pharm. Pharmacol., 25,820 (1973)(2β,5α,6β,17ξ,18α)-13-Methoxyvoaluteine Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
(2β,5α,6β,17ξ,18α)-13-Methoxyvoaluteine Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 0)Lieferanten
Firmenname | Telefon | Land | Produktkatalog | Edge Rate |
---|
- (2β,5α,6β,17ξ,18α)-13-Methoxyvoaluteine
- Conopharyngine pseudoindoxyl
- Spiro[2H-indole-2,4'-[4H-1,6]methanoquinoline]-4'a(5'H)-carboxylic acid, 8'-ethyl-1,2',3,3',6',7',8',8'a-octahydro-5,6-dimethoxy-3-oxo-, methyl ester, (1'S,4'aS,6'R,8'R,8'aS)- (9CI)
- 52579-71-2